Results of peginterferon alpha-2a treatment in patients with chronic hepatitis B in the Western part of Romania

Abstract

Objective: Currently there are two major types of antiviral therapy in HBV chronic liver disease: PegInterferon alpha-2a and nucleoside/ nucleotide agents. The aim of this study was to evaluate the response to PegInterferon alfa-2a treatment, in patients with chronic hepatitis B. Material and Methods: We performed a retrospective study on a group of 277 patients with chronic hepatitis B. The indication for treatment was made according to national and international guidelines. Only patients treated for 48 weeks with PegInterferon alpha-2a and in whom a viral load at least 6 months after the end of treatment was available, were included in our study. We defined as complete sustained viral response (complete SVR) an undetectable viral load at least 6 months after the end of treatment and as a partial sustained viral response (partial SVR) a viral load less than 2000 IU/mL (10000 copies/ml) at 6 months or more after the end of treatment. Results: Of the 277 patients, 206 (74.4%) were HBeAg negative and the remaining 71 (25.6%) HBeAg positive. 17.4% (36/206) of HBeAg negative patients treated had SVR, while 11.3% (8/71) of the HBeAg positive patients had SVR (p=0.2612). Among HBeAg negative patients, 2.9% (6/206) had complete SVR and 14.5% (30/206) had partial SVR. In patients with positive HBeAg, complete SVR occurred in 1.4% (1/71) cases and partial SVR in 9.9% (7/71). Conclusion: Our study showed a low rate of SVR in patients with HBV chronic liver disease following PegInterferon treatment, with no significant differences between those with HBeAg + or HBeAg-.

Keywords

• Chronic hepatitis B
• PegInterferon alpha 2a
• Sustained Viral Response (SVR)